The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBAGR.L Regulatory News (BAGR)

  • There is currently no data for BAGR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proposed Private Placement and Bank Refinancing

25 Jul 2016 16:35

RNS Number : 1704F
Bagir Group Ltd
25 July 2016
 

25 July 2016

 

 

Bagir Group Ltd.

("Bagir" or the "Company")

 

Announces Proposed Private Placement, Bank Refinancing

and

Trading Update

 

Bagir (AIM: BAGR), a designer, creator and provider of innovative tailoring, is pleased to announce, as part of the Company's Recovery Plan, an agreement with its lenders, Bank Leumi and Discount Bank to clear all outstanding bank debt (approximately $21 million). Additionally, the Company intends to undertake a private placement to raise approximately $8.5 million ("Private Placement").

 

"During the recent months we have been working closely with both of our lenders to address the imbalance between the size of the business and its current level of borrowings. Today, we are pleased to be announcing a new plan under which the outstanding borrowings will be partially repaid and the balance written off which will enable the Company to strengthen its financial position, support its operating cash flow and once again invest in growing the business. We are grateful to our lenders for working collaboratively on this," said Eran Itzhak, Chief Executive Officer of Bagir.

 

Agreement with Lenders

 

· Under the agreement the Company's two principal lenders have agreed to accept a partial repayment and then to write-off the balance of all bank loans amounting to approximately $21 million and associated obligations, subject to the Company fulfilling the following conditions to them pro rata before 31 December 2016:

 

o Cash payment of $6.3 million to be funded from the proposed Private Placement ("Cash Payment").

o Allocation to the lenders of 8.33% of the Company's total issued share capital post the completion of the Private Placement.

 

· On receipt of the Cash Payment and issue of new ordinary shares to the banks, each of the banks shall write-off the outstanding balance of the obligations and liabilities of the Company to the banks and any liens, mortgages, and guarantees created in favor of the banks, will also be cancelled.

 

· Additionally, if the Company generates annual EBITDA above $6.5 million between 2016 and 2024 then a contingent payment will be due of 50% of the excess of annual EBITDA generated above $6.5 million up to a maximum payment in aggregate of $8.0 million.

 

 

Proposed Private Placement

 

· The Company intends to raise approximately $8.5 million (before expenses) by way of a Private Placement from both existing and new shareholders.

 

· Of the net proceeds from the Private Placement $6.3 million will be used to repay the lenders and the balance will be used as working capital to support the business operations.

 

· The Private Placement is interdependent on the completion of the Bank Refinancing.

 

· Completion of the Private Placement is subject inter alia to shareholder approval, which will be sought at a General Meeting of the Company. Details will be made available to shareholders in due course.

 

Update on Current Trading

 

· Trading in H1 2016 has been in line with management expectations in both the US and the UK markets and the Company is expecting positive EBITDA for this period compared to a loss in the prior year.

 

· The Company continues to make good progress under the Recovery Plan set out to shareholders in the full year results announcement with a key focus on:

 

o Targeting new clients from amongst the larger players in US and UK retail markets.

o Securing high volume sale orders supported by a new pricing model.

o Further expansion of operations at the Company's chosen production sites in Egypt, Vietnam and Ethiopia, to maximise the potential for customs and tariff-free trade.

 

· The Company's interim results are expected to be announced in September 2016.

 

 

Commenting on the announcement, Eran Itzhak, said, "This is a significant point in the recovery of the business, one which creates a new platform for the business to grow from. Bagir has fifty years of trading history and skill in providing quality, uniquely designed and innovatively tailored products to leading retailers globally. The fundamentals of the business remain strong and with a new financial base we would expect to accelerate our ability to re-build the business.

 

We will now proceed to put forward our proposals for the bank refinancing and for the equity raising to new and existing investors and we look forward to providing a further update on our progress."

 

For further information, please contact:

 

Bagir Group Ltd.

Eran Itzhak, Chief Executive Officer

Udi Cohen, Chief Financial Officer

Tessa Laws, Non-Executive Chairman

 

via Novella Communications on:

+44 (0) 20 3151 7008

N+1 Singer

Nic Hellyer

Alex Price

 

+44 (0) 20 7496 3000

Novella

Tim Robertson

Toby Andrews

+44 (0) 20 3151 7008

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTAKPDNPBKDBOB
Date   Source Headline
18th May 20205:30 pmRNSBagir Group
18th May 202012:10 pmRNSAppointment of Liquidator
22nd Apr 20207:00 amRNSAppointment of Court Trustees
14th Apr 20207:00 amRNSFinancial Update
3rd Apr 20207:30 amRNSSuspension - Bagir Group Ltd
3rd Apr 20207:30 amRNSFinancial Update
31st Mar 20207:00 amRNSHolding(s) in Company
25th Mar 202012:00 pmRNSCOVID-19 Update
23rd Mar 20209:03 amRNSHolding(s) in Company
17th Mar 20201:24 pmRNSHolding(s) in Company
16th Mar 20208:20 amRNSHolding(s) in Company
2nd Mar 202011:20 amRNSHolding(s) in Company
21st Feb 20207:00 amRNSUpdate on status with Shandong Ruyi and 19 Trading
13th Feb 20208:18 amRNSResignation of Chairperson
21st Jan 20207:55 amRNSHolding(s) in Company
13th Dec 20192:06 pmRNSHolding(s) in Company
2nd Dec 201911:02 amRNSResult of AGM
29th Nov 20198:20 amRNSHolding(s) in Company
22nd Oct 20199:46 amRNSNotice of AGM
7th Oct 20199:17 amRNSHolding(s) in Company
3rd Oct 20194:40 pmRNSSecond Price Monitoring Extn
3rd Oct 20194:35 pmRNSPrice Monitoring Extension
2nd Oct 20193:29 pmRNSHolding(s) in Company
2nd Oct 20193:20 pmRNSHolding(s) in Company
26th Sep 20197:00 amRNSHalf-year Report
10th Sep 201911:30 amRNSHolding(s) in Company
10th Sep 201910:55 amRNSHolding(s) in Company
5th Sep 201910:35 amRNSHolding(s) in Company
23rd Aug 20193:08 pmRNSHolding(s) in Company
19th Aug 20193:48 pmRNSHolding(s) in Company
12th Aug 20193:49 pmRNSHolding(s) in Company
12th Aug 20198:49 amRNSHolding(s) in Company
28th Jun 20197:00 amRNSPosting of Annual Report
25th Jun 20197:00 amRNSDirectorate Change
19th Jun 20197:00 amRNSUpdate on Strategic Partnership and Trading
31st May 201911:05 amRNSSecond Price Monitoring Extn
31st May 201911:00 amRNSPrice Monitoring Extension
31st May 20197:00 amRNSUpdate on Strategic Partnership
28th May 20192:05 pmRNSSecond Price Monitoring Extn
28th May 20192:00 pmRNSPrice Monitoring Extension
20th May 20194:40 pmRNSSecond Price Monitoring Extn
20th May 20194:35 pmRNSPrice Monitoring Extension
13th May 20197:00 amRNSDirectorate Change
4th Apr 20197:00 amRNSFinal Results
22nd Mar 201912:01 pmRNSHolding(s) in Company
15th Feb 201910:38 amRNSHolding(s) in Company
13th Feb 20192:00 pmRNSPrice Monitoring Extension
13th Feb 20197:00 amRNSUpdate on strategic partnership
3rd Jan 20192:05 pmRNSSecond Price Monitoring Extn
3rd Jan 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.